Monitoring and Management of Corneal Events During Treatment with Blenrep

Patients Receiving Blenrep (belantamab mafodotin-blimf) Require Monitoring By Eye Care Professionals

**WARNING: OCULAR TOXICITY**
Blenrep caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes. Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold Blenrep until improvement and resume, or permanently discontinue, based on severity. Because of the risk of ocular toxicity, Blenrep is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Blenrep REMS.

**Dosage Modifications for Corneal Adverse Reactions per the KVA Scale**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Corneal Adverse Event (Reported by an Eye Care Professional)</th>
<th>Recommended Dosage Modifications (To be made by Hematologist/Oncologist)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Corneal examination finding(s): Mild superficial keratopathy*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Change in BCVA**: Decline from baseline of 1 line on Snellen Visual Acuity</td>
<td>Continue treatment at current dose</td>
</tr>
<tr>
<td>2</td>
<td>Corneal examination finding(s): Moderate superficial keratopathy* Change in BCVA**: Decline from baseline by 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200</td>
<td>Withhold Blenrep until improvement in both corneal examination findings and changes in BCVA to Grade 1 or better and resume at same dose</td>
</tr>
<tr>
<td>3</td>
<td>Corneal examination finding(s): Severe superficial keratopathy* Change in BCVA**: Decline from baseline by more than 3 lines on Snellen Visual Acuity and not worse than 20/200</td>
<td>Withhold Blenrep until improvement in both corneal examination findings and changes in BCVA to Grade 1 or better and resume at a reduced dose</td>
</tr>
<tr>
<td>4</td>
<td>Corneal examination finding(s): Corneal epithelial defect* Corneal examination finding(s): Snellen Visual Acuity worse than 20/200</td>
<td>Consider permanent discontinuation of Blenrep. If continuing treatment withhold Blenrep until improvement in both corneal examination findings and change in BCVA to Grade 1 or better and resume at reduced dose</td>
</tr>
</tbody>
</table>

*Mild superficial keratopathy (documented worsening from baseline) with or without symptoms; **Changes in visual acuity due to treatment-related corneal findings; *Moderate superficial keratopathy with or without patchy microcyst-like deposits, sub-epithelial haze (peripheral), or a new peripheral stromal opacity; *Severe superficial keratopathy with or without diffuse microcyst-like deposits, subepithelial haze (central), or a new central stromal opacity; *Corneal epithelial defect such as corneal ulcers

**Monitoring Corneal Events**

- **First dose**
  - Baseline exam (prior to starting treatment)
  - Exam (prior to each dose)
- **Second dose**
  - Baseline exam (prior to starting treatment)
  - Exam (prior to each dose)
- **Third dose**
  - Baseline exam (prior to starting treatment)
  - Exam (prior to each dose)
- **Ongoing treatment**
  - Baseline exam (prior to each dose)
  - Exam (prior to each dose)

- Patients must have an ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Perform baseline examinations within 3 weeks prior to the first dose.
- Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose.
- **Blenrep** is given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity.

**Supportive Care and Patient Counseling**

- Use of preservative-free lubricant eye drops at least 4 times a day starting with the first infusion and continuing until end of treatment.
- Advise patients to avoid wearing contact lenses during treatment with Blenrep unless directed by an ophthalmologist.
- Advise patients to use caution when driving or operating machinery as Blenrep may affect their vision.

**References:**
1. GlaxoSmithKline Local Label

Some information contained in this response may not be included in the approved Prescribing Information. This response is not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. In order for GlaxoSmithKline to monitor the safety of our products, we encourage healthcare professionals to report adverse events or suspected overdoses to the company at 888-826-5249. This response was developed according to the principles of evidence-based medicine and, therefore, references may not be all-inclusive. The Prescribing Information, including the boxed warning(s) can be accessed at this link or at GSK Products.